Abstract
Objective: The aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the patient perspective, (2) investigate MP-AzeFlu use in real life and its impact on patients’ lives and (3) explore factors associated with treatment satisfaction.
Methods: A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven European countries (March–June 2019). Questions explored AR burden and treatment satisfaction. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM- 9; max score 1⁄4 100). Participants (aged !18years) had a doctor/healthcare provider confirmed AR diagnosis and used MP-AzeFlu within the last year.
Results: Pre-MP-AzeFlu treatment, participants (n1⁄41004) reported an average of 3.3 (SD:3.5) doctor visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR. Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of partici- pants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy. Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively. 70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s), and !70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0 (SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were significantly improved when MP-AzeFlu was taken as recommended.
Conclusions: The impact of AR on patients’ lives remains high. Real-life use of MP-AzeFlu reduces that impact and is associated with a high level of effectiveness, convenience and global satisfaction.
Methods: A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven European countries (March–June 2019). Questions explored AR burden and treatment satisfaction. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM- 9; max score 1⁄4 100). Participants (aged !18years) had a doctor/healthcare provider confirmed AR diagnosis and used MP-AzeFlu within the last year.
Results: Pre-MP-AzeFlu treatment, participants (n1⁄41004) reported an average of 3.3 (SD:3.5) doctor visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR. Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of partici- pants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy. Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively. 70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s), and !70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0 (SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were significantly improved when MP-AzeFlu was taken as recommended.
Conclusions: The impact of AR on patients’ lives remains high. Real-life use of MP-AzeFlu reduces that impact and is associated with a high level of effectiveness, convenience and global satisfaction.
| Original language | English |
|---|---|
| Pages (from-to) | 1259-1272 |
| Number of pages | 14 |
| Journal | Current Medical Research and Opinion |
| Volume | 37 |
| Issue number | 7 |
| Early online date | 20 Apr 2021 |
| DOIs | |
| Publication status | Published - 20 Apr 2021 |
Bibliographical note
Funding for this research was provided by Mylan Inc.Acknowledgements
We thank Dr Ruth B Murray (Medscript NZ Ltd) for assistance in drafting and editing this manuscript.
Keywords
- Austria
- Finland
- germany
- ireland
- italy
- Norway
- patient satisfaction
- TSQM
- UK